Amgen Inc. $AMGN Stock Holdings Lifted by Capital Research Global Investors

Capital Research Global Investors boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,731,290 shares of the medical research company’s stock after purchasing an additional 122,631 shares during the quarter. Capital Research Global Investors owned about 0.88% of Amgen worth $1,335,168,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares during the period. Sivia Capital Partners LLC raised its stake in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after acquiring an additional 114 shares in the last quarter. Schnieders Capital Management LLC. lifted its holdings in shares of Amgen by 29.3% during the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after acquiring an additional 5,853 shares during the period. Vestmark Advisory Solutions Inc. boosted its stake in shares of Amgen by 373.3% in the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 4,842 shares of the medical research company’s stock valued at $1,352,000 after purchasing an additional 3,819 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Amgen in the 2nd quarter valued at $706,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Royal Bank Of Canada upped their price objective on Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a report on Wednesday, February 4th. The Goldman Sachs Group upped their target price on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, February 4th. Cantor Fitzgerald raised their target price on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Barclays started coverage on shares of Amgen in a research note on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. Finally, Guggenheim raised their price objective on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $354.17.

Amgen Stock Performance

Shares of AMGN stock opened at $376.97 on Tuesday. The business’s 50-day moving average price is $354.21 and its 200-day moving average price is $323.38. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The firm has a market capitalization of $203.21 billion, a price-to-earnings ratio of 26.49, a PEG ratio of 3.67 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.